Kenvue Inc. (NYSE:KVUE) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank decreased its position in Kenvue Inc. (NYSE:KVUE) by 11.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 911,371 shares of the company’s stock after selling 118,710 shares during the period. Toronto Dominion Bank’s holdings in Kenvue were worth $19,457,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares during the period. Vanguard Group Inc. lifted its stake in Kenvue by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock valued at $4,665,908,000 after acquiring an additional 1,636,741 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after acquiring an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock valued at $980,989,000 after acquiring an additional 1,391,854 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 0.8%

Shares of KVUE stock opened at $23.99 on Tuesday. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17. The company has a market cap of $46.03 billion, a price-to-earnings ratio of 45.26, a PEG ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a 50 day simple moving average of $23.18 and a 200-day simple moving average of $22.60.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.69 billion. During the same period in the prior year, the business posted $0.28 earnings per share. The firm’s revenue for the quarter was down 3.9% on a year-over-year basis. On average, equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date is Wednesday, May 14th. Kenvue’s dividend payout ratio is presently 149.09%.

Analyst Ratings Changes

A number of research firms recently issued reports on KVUE. Barclays boosted their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a research report on Monday, May 12th. UBS Group upped their target price on Kenvue from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Friday, May 9th. Citigroup lifted their price target on Kenvue from $22.00 to $24.50 and gave the company a “neutral” rating in a research report on Friday, May 9th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Finally, Evercore ISI assumed coverage on shares of Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.